Eckert & Ziegler posted Q1 2026 sales of €72.90 million, up 7% YoY, and net income of €10.40 million.
Adjusted EBIT fell 2% due to a weaker product mix in the Isotope Products segment despite overall revenue growth.
The Medical segment drove sales increase, with higher revenue from pharmaceutical radioisotopes, generators, and CDMO services.
Company reaffirmed FY2026 guidance of ~€320 million sales and ~€80 million adjusted EBIT.